Mahamaya Lifesciences Ltd
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]
- Market Cap ₹ 370 Cr.
- Current Price ₹ 158
- High / Low ₹ 205 / 111
- Stock P/E 22.4
- Book Value ₹ 52.1
- Dividend Yield 0.00 %
- ROCE 20.0 %
- ROE 19.3 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 90 | 137 | 161 | 264 | 329 | |
| 84 | 128 | 148 | 241 | 296 | |
| Operating Profit | 6 | 9 | 13 | 23 | 34 |
| OPM % | 7% | 6% | 8% | 9% | 10% |
| 0 | 0 | 1 | 3 | 1 | |
| Interest | 2 | 3 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 4 | 5 | 7 | 17 | 24 |
| Tax % | 27% | 26% | 27% | 25% | 31% |
| 3 | 4 | 5 | 13 | 17 | |
| EPS in Rs | 21.78 | 30.03 | 41.80 | 7.28 | 7.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 34% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 24% |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 18 | 23 |
| Reserves | 14 | 18 | 23 | 32 | 99 |
| 19 | 24 | 55 | 58 | 91 | |
| 21 | 34 | 33 | 81 | 98 | |
| Total Liabilities | 56 | 78 | 112 | 188 | 310 |
| 20 | 21 | 21 | 27 | 38 | |
| CWIP | 2 | 2 | 3 | 4 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 34 | 54 | 88 | 157 | 267 | |
| Total Assets | 56 | 78 | 112 | 188 | 310 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 2 | 1 | -23 | 1 | -30 | |
| -3 | -3 | -2 | -8 | -16 | |
| 1 | 2 | 24 | 9 | 81 | |
| Net Cash Flow | 0 | 1 | -0 | 1 | 35 |
| Free Cash Flow | -1 | -2 | -25 | -8 | -46 |
| CFO/OP | 56% | 24% | -163% | 12% | -75% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 37 | 25 | 64 | 67 | 78 |
| Inventory Days | 93 | 109 | 137 | 167 | |
| Days Payable | 83 | 87 | 61 | 92 | |
| Cash Conversion Cycle | 47 | 48 | 140 | 142 | 78 |
| Working Capital Days | 8 | 9 | 14 | 29 | 49 |
| ROCE % | 20% | 21% | 26% | 20% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
26 May - Mahamaya Lifesciences issued FY26 audited results on May 26, 2026; revenue rose 25% to Rs 32,887.30 lakh.
-
The Audited (Standalone & Consolidated) Financial Results Of The Company For The Half Year And Financial Year Ended 31.03.2026 Along With The Audit Reports Thereon
25 May - Board approved audited FY26 standalone and consolidated results; consolidated profit rose to ₹1,652.33 lakh on ₹32,887.30 lakh revenue.
-
Board Meeting Outcome for Audited Financial Results (Standalone & Consolidated) For The Half Year And Year Ended On 31.03.2026
25 May - Board approved audited standalone and consolidated results for half-year and year ended 31 March 2026.
-
Board Meeting Intimation for Prior Intimation Of The Board Meeting Pursuant To Regulation 29(1) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015
20 May - Board meeting on May 25, 2026 to approve audited standalone and consolidated FY26 results.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
15 May - Monitoring Agency Report for IPO proceeds: Rs 61.96 crore issue, no deviations, 32.79 crore unutilised till March 31, 2026.
Annual reports
No data available.
Business Profile[1]
The company manufactures pesticide formulations and supplies bulk products to Indian agrochemical companies and multinational corporations (MNCs). It imports scientifically researched molecules, secures registrations with the Central Insecticides Board, and develops these molecules into technical-grade and value-added formulations, which are marketed to domestic manufacturers and global MNCs.